Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust ...
Enveric Biosciences, Inc. is a NASDAQ-listed biotechnology company dedicated to translating cannabinoid science and neuroplastogenic small-molecule research into potential therapeutic products. The company’s described focus includes advancing diverse cannabinoid-based medications primarily for cancer care, alongside a broader platform framed around neuroplastogenic therapies for neuropsychiatric disorders. From a business and product ...Enveric Biosciences, Inc. is a NASDAQ-listed biotechnology company dedicated to translating cannabinoid science and neuroplastogenic small-molecule research into potential therapeutic products. The company’s described focus includes advancing diverse cannabinoid-based medications primarily for cancer care, alongside a broader platform framed around neuroplastogenic therapies for neuropsychiatric disorders.
From a business and product perspective, Enveric’s pipeline highlights multiple development programs. In the cannabinoid-focused oncology/care area, the company has indicated candidates such as EV104 for osteoarthritis and EVM-101 and EVM-201 intended to address cancer-related distress. It also references EVM-301 under development for a mental health indication, EV102 as a cannabinoid cream formulated for topical skin use, and EV101 as a combination therapy concept pairing cannabinoids with chemotherapy. Collectively, these programs suggest a strategy aimed at leveraging cannabinoid mechanisms for both systemic and localized treatment contexts, while also exploring combination approaches that may complement existing oncology regimens.
In terms of how Enveric typically creates value, the core activities are research and development—identifying compounds, progressing them through preclinical and clinical stages, and protecting intellectual property. This model is generally characterized by high R&D intensity, significant spending on scientific work, study design, patient recruitment/clinical execution, regulatory interactions, and ongoing formulation/development. The company’s cost and “BOM” (as applicable to drug development) is less about manufacturing mass quantities early on and more about the cost structure of drug discovery and development: laboratory work, specialized formulation, clinical materials, regulatory documentation, and patent/IP maintenance.
Financially, provided market data indicates the company has experienced losses (e.g., negative return metrics and free cash flow figures in the snapshot), which is common for early-to-mid development life sciences firms. Accordingly, capital needs often rely on equity financing, partnerships, and/or milestone-based funding rather than near-term cash generation from product sales.
Key people include CEO and Director Joseph Tucker, Ph.D., who is described as a seasoned, serial biotech executive. Looking ahead, Enveric’s “wishes” and practical objectives in this type of company normally center on demonstrating clinical efficacy and safety signals, advancing pipeline candidates toward regulatory submissions, securing funding/partners to support trials, and strengthening the defensibility of its IP portfolio. With an R&D-driven approach across multiple therapeutic candidates, the near-term operational priorities are generally tied to clinical progress and the ability to translate preclinical or early clinical hypotheses into scalable, approvable therapies.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-12.1M
-26.7%
-85.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-8.1M
-5.4%
-8.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
5.38x
+192.8%
-12.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
